LRRK2-mediated NLRC4 phosphorylation differentially regulates IL-1β/IL-18 secretion

Area of Science:

• Immunology
• Molecular Biology
• Gastroenterology

Background:

• The NLRC4 inflammasome plays a critical role in innate immunity and inflammatory diseases.
• LRRK2 kinase activity is implicated in inflammatory conditions, including Crohn's disease (CD).
• The precise relationship between LRRK2 and NLRC4 inflammasome function remains incompletely understood.

Purpose of the Study:

• To investigate the role of LRRK2-kinase phosphorylation in NLRC4 inflammasome activation and function.
• To explore the impact of LRRK2-mediated NLRC4 inflammasome regulation on IL-1β and IL-18 production.
• To examine the therapeutic potential of LRRK2 inhibition in modulating NLRC4 inflammasome activity in Crohn's disease models.

Main Methods:

• Analysis of LRRK2-kinase phosphorylation of the NLRC4 inflammasome in human and murine cells.
• Assessment of inflammasome activation and cytokine production (IL-1β, IL-18) following LRRK2 inhibition.
• Studies in wild-type and genetically modified mice to evaluate NLRC4 inflammasome-induced gut barrier dysfunction.

Main Results:

• LRRK2-kinase is essential and sufficient for NLRC4 inflammasome phosphorylation, requiring ASC association.
• LRRK2 inhibition impairs IL-1β production by modulating pro-IL-1β cleavage but not IL-18 production.
• Increased NLRC4 inflammasome activation and LRRK2-dependent IL-1β secretion were observed in cells from CD patients.
• NLRC4 inflammasome activation impairs gut barrier function, an effect abrogated by LRRK2-kinase inhibition.

Conclusions:

• LRRK2-kinase phosphorylation is a key regulator of NLRC4 inflammasome function, specifically impacting IL-1β production.
• LRRK2 inhibition demonstrates therapeutic potential by mitigating NLRC4-mediated gut barrier dysfunction in CD.
• Targeting LRRK2 offers a strategy to selectively modulate inflammasome activity and ameliorate inflammatory pathology.